Table 5.
Recommendation for MIC of 0.5 mg/L (MIC90 of our hospital).
| CrCl (mL/min) | Regimens (TDDs*) | PTA (%) | CFR (%) | AKI Risk (%) | Alternative Regimens (TDDs*) | PTA (%) | CFR (%) | AKI Risk (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EOT | D7 | EOT | D7 | |||||||
| 101–130 | 100 mg Q6h (400 mg) | 90.93 | 90.09 | 43.38 | 30.33 | |||||
| 80–100 | 100 mg Q8h (300 mg) | 91.79 | 90.94 | 42.57 | 30.66 | 150 mg Q12h (300 mg) (US-FDA) | 91.32 | 90.47 | 36.59 | 26.24 |
| 51–79 | 100 mg Q12h (200 mg) | 93.7 | 92.84 | 38.44 | 26 | |||||
| 30–50 | 100 mg Q24h (100 mg) | 93.77 | 92.87 | 19.07 | 11.46 | |||||
| 11–29 | 66 mg Q24h (66 mg) | 97.33 | 96.42 | 23.17 | 13.08 | |||||
| 1–10 | 33 mg Q24h (33 mg) | 95.6 | 94.65 | 17.79 | 9.52 | |||||
TDDs*: total daily doses in mg of colistin base activity, Q: every, PTA: probability of target attainment, CFR: cumulative fraction of response, AKI: acute kidney injury, CrCl: creatinine clearance, MIC90: minimum inhibitory concentration required to inhibit the growth of 90% of organisms, EOT: end of treatment, D7: at day 7, US-FDA: Food and Drug Administration of United State.